CureDuchenne Webinar with REGENXBIO: Update on Affinity Duchenne study and RGX-202, an investigational gene therapy for Duchenne
Date & Time May 19, 2026 10:00 AM in
In this webinar, Dr. Johannaz (Naz) Dastgir, Executive Medical Director and Clinical Development Lead for RGX-202 at REGENXBIO, shares an update on RGX-202, their investigational gene therapy program for Duchenne muscular dystrophy and their Affinity Duchenne research trial.
We use cookies to ensure that we give you the best experience on our website. By continuing to use this site you are agreeing to accept our use of cookies. For more information about cookies please visit our Privacy Policy page.I Agree